Aquestive Therapeutics (NASDAQ:AQST) Delivers Shareholders Favorable 85% Return Over 1 Year, Surging 23% in the Last Week Alone

Aquestive Therapeutics, Inc. (NASDAQ:AQST) shareholders might be concerned after seeing the share price drop 22% in the last quarter. While that might be a setback, it doesn't negate the nice

Simply Wall StJul 17 10:28 ET

Express News | JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target

BenzingaJun 26 12:03 ET

JMP Securities Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9

JMP Securities analyst Jason Butler maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 38

Moomoo NewsJun 25 16:32 ET · Ratings

Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows

On Tuesday, Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film.Anaphylm

BenzingaJun 25 13:00 ET

Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $7

Lake Street analyst Thomas Flaten maintains $Aquestive Therapeutics(AQST.US)$ with a buy rating, and adjusts the target price from $8 to $7.According to TipRanks data, the analyst has a success rate o

Moomoo NewsJun 25 09:33 ET · Ratings

Aquestive Gains After Initial Data for Allergy Candidate

Seeking AlphaJun 25 09:29 ET